カテゴリ： MarketLine, スイス, 企業調査

CRISPR Therapeutics：戦略・SWOT・企業財務分析

◆英語タイトル：CRISPR Therapeutics - Strategy, SWOT and Corporate Finance Report
◆商品コード：DATA8015021
◆発行会社（調査会社）：MarketLine
◆発行日：2017年9月30日
◆ページ数：47
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：スイス
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single UserUSD175 ⇒換算￥25,900見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD350 ⇒換算￥51,800見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD525 ⇒換算￥77,700見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はMarketLine社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※MarketLine社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

CRISPR Therapeutics – Strategy, SWOT and Corporate Finance Report
Summary

CRISPR Therapeutics – Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company’s structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company.

Key Highlights

CRISPR Therapeutics AG (CRISPR or “the company”) is a biopharmaceutical company created to translate CRISPR-Cas9, a breakthrough gene-editing technology, into transformative medicines for serious human diseases. The company classifies its business into single operating segment: the business of discovering, developing and commercializing therapies derived from or incorporating genome-editing technology. Through its CRISPR/Cas9 gene-editing technology, the company allows selective deletion, modification or correction of a disease causing abnormality in a specific DNA segment. It primarily operates in Switzerland, the UK, and the US. The company is headquartered in Basel, Switzerland.

Scope

- Detailed information on CRISPR Therapeutics required for business and competitor intelligence needs
- A study of the major internal and external factors affecting CRISPR Therapeutics in the form of a SWOT analysis
- An in-depth view of the business model of CRISPR Therapeutics including a breakdown and examination of key business segments
- Intelligence on CRISPR Therapeutics’s mergers and acquisitions (MandA), strategic partnerships and alliances, capital raising, private equity transactions, and financial and legal advisors
- News about CRISPR Therapeutics, such as business expansion, restructuring, and contract wins
- Large number of easy-to-grasp charts and graphs that present important data and key trends

Reasons to buy

- Gain understanding of CRISPR Therapeutics and the factors that influence its strategies.
- Track strategic initiatives of the company and latest corporate news and actions.
- Assess CRISPR Therapeutics as a prospective partner, vendor or supplier.
- Support sales activities by understanding your customers’ businesses better.
- Stay up to date on CRISPR Therapeutics’s business structure, strategy and prospects.

【レポートの目次】

Table of Contents
Company Snapshot
CRISPR Therapeutics: Company Overview
CRISPR Therapeutics: Overview and Key Facts
CRISPR Therapeutics: Overview
CRISPR Therapeutics: Key Facts
CRISPR Therapeutics: Key Employees
CRISPR Therapeutics: Key Employee Biographies
CRISPR Therapeutics: Major Products and Services
CRISPR Therapeutics: Company History
CRISPR Therapeutics: Management Statement
CRISPR Therapeutics: Key Competitors
CRISPR Therapeutics: Company Analysis
CRISPR Therapeutics: Business Description
CRISPR Therapeutics: SWOT Analysis
CRISPR Therapeutics: SWOT Overview
CRISPR Therapeutics: Strengths
CRISPR Therapeutics: Weaknesses
CRISPR Therapeutics: Opportunities
CRISPR Therapeutics: Threats
CRISPR Therapeutics: Corporate Financial Deals Activity
CRISPR Therapeutics: Financial Deals Overview
CRISPR Therapeutics: Targets and Partners
CRISPR Therapeutics: Top Deals 2013 – 2017YTD*
CRISPR Therapeutics: Advisors
CRISPR Therapeutics: Top Legal Advisors
CRISPR Therapeutics: Top Financial Advisors
CRISPR Therapeutics: Capital Raising
CRISPR Therapeutics: Partnership
CRISPR Therapeutics: Private Equity and Ownership
CRISPR Therapeutics: Recent Developments
CRISPR Therapeutics: News and Events Summary
CRISPR Therapeutics: Business Expansion
CRISPR Therapeutics: Corporate Governance
CRISPR Therapeutics: Financial Deals
CRISPR Therapeutics: Financial Performance
CRISPR Therapeutics: Grants
CRISPR Therapeutics: Market Developments
CRISPR Therapeutics: Regulatory and Legal Events
CRISPR Therapeutics: Research & Development
CRISPR Therapeutics: Strategy and Operations
Appendix
Contact Us
Methodology
Definitions
About MarketLine

List of Tables
Table 1: CRISPR Therapeutics: Key Facts
Table 2: CRISPR Therapeutics: Key Employees
Table 3: CRISPR Therapeutics: Key Competitors
Table 4: CRISPR Therapeutics: Deal Activity by Deal Type - Volume (TTM*)
Table 5: CRISPR Therapeutics: Deal Activity by Deal Type - Volume (2013 - YTD*2017)
Table 6: CRISPR Therapeutics: Targets and Partners
Table 7: CRISPR Therapeutics: Top Deals 2013 - 2017YTD*
Table 8: CRISPR Therapeutics: Legal Advisor Ranking by Value (US$m)
Table 9: CRISPR Therapeutics: Financial Advisor Ranking by Value (US$m)
Table 10: CRISPR Therapeutics: Capital Raising Volume and Value Trend (2013 - YTD*2017)
Table 11: CRISPR Therapeutics: Capital Raising by Deal Type (2013 - YTD*2017)
Table 12: CRISPR Therapeutics: Partnership Volume and Value Trend (2013 - YTD*2017)
Table 13: CRISPR Therapeutics: Partnership Trend by Deal Type (2013 - YTD*2017)
Table 14: CRISPR Therapeutics: Private Equity and Ownership Volume and Value Trend (2013 - YTD*2017)
Table 15: CRISPR Therapeutics: Private Equity and Ownership Volume by Deal Type (2013 - YTD*2017)
Table 16: CRISPR Therapeutics: News and Events Summary
Table 17: CRISPR Therapeutics: Business Expansion
Table 18: CRISPR Therapeutics: Corporate Governance
Table 19: CRISPR Therapeutics: Financial Deals
Table 20: CRISPR Therapeutics: Financial Performance
Table 21: CRISPR Therapeutics: Grants
Table 22: CRISPR Therapeutics: Market Developments
Table 23: CRISPR Therapeutics: Regulatory and Legal Events
Table 24: CRISPR Therapeutics: Research & Development
Table 25: CRISPR Therapeutics: Strategy and Operations

★海外企業調査レポート[CRISPR Therapeutics：戦略・SWOT・企業財務分析]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Invivo Corp-医療機器分野：企業M&A・提携分析
    Summary Invivo Corp (Invivo), a subsidiary of Koninklijke Philips NV is a medical device company that designs, manufactures, and markets patient monitoring systems. The company offers products in various categories such as advanced visualization systems, breast imaging and biopsy solutions, neuro im …
  • Mitralign Inc：医療機器：M&Aディール及び事業提携情報
    Summary Mitralign Inc (Mitralign) is a medical device company that offers direct transcatheter annuloplasty system to treat both functional tricuspid regurgitation and mitral regurgitation. The company’s products include crossing wire, pledget delivery catheter and placation lock delivery catheter, …
  • IJM Land Berhad：企業の戦略・SWOT・財務情報
    IJM Land Berhad - Strategy, SWOT and Corporate Finance Report Summary IJM Land Berhad - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • CESC Limited：企業の戦略・SWOT・財務分析
    CESC Limited - Strategy, SWOT and Corporate Finance Report Summary CESC Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Harte Hanks Inc (HHS)：企業の財務・戦略的SWOT分析
    Harte Hanks Inc (HHS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • JACCS Co Ltd：企業の戦略・SWOT・財務分析
    JACCS Co Ltd - Strategy, SWOT and Corporate Finance Report Summary JACCS Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Enzo Clinical Labs Inc：医療機器：M&Aディール及び事業提携情報
    Summary Enzo Clinical Labs Inc (Enzo Clinical), a subsidiary of Enzo Biochem Inc, is a medical laboratory that provides testing services. The company develops technologies in the areas of gene regulation and gene modification, biomedical and pharmaceutical research markets, among others. It provides …
  • Sony Corporation：企業の戦略・SWOT・財務情報
    Sony Corporation - Strategy, SWOT and Corporate Finance Report Summary Sony Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • AVX Corporation (AVX)：企業の財務・戦略的SWOT分析
    AVX Corporation (AVX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Kallpa Generacion SA：企業の戦略的SWOT分析
    Kallpa Generacion SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Ulthera Inc：医療機器：M&Aディール及び事業提携情報
    Summary Ulthera Inc (Ulthera), a subsidiary of Merz Pharma GmbH & Co KgaA is a medical device company that develops and commercializes technologies for aesthetic and medical applications by using its therapeutic ultrasound platform technologies. The company’s therapeutic ultrasound platform technolo …
  • Iwatani Corporation (8088)：企業の財務・戦略的SWOT分析
    Iwatani Corporation (8088) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • 3E sanv：企業の戦略的SWOT分析
    3E sanv - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. This …
  • Haci Omer Sabanci Holding A.S. (SAHOL)：企業の財務・戦略的SWOT分析
    Haci Omer Sabanci Holding A.S. (SAHOL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths a …
  • SK Telecom Co., Ltd.：企業の戦略・SWOT・財務分析
    SK Telecom Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary SK Telecom Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Kadimastem Ltd (KDST)：製薬・医療：M&Aディール及び事業提携情報
    Summary Kadimastem Ltd (Kadimastem) is a clinical stage biopharmaceutical company that develops industrial regenerative medicines to treat neuro-degenerative diseases. Its technology platform enables the manufacturing of islet-like endocrine cells (differentiated cells) and glia restricted progenito …
  • International SOS Pte Ltd：企業の戦略的SWOT分析
    International SOS Pte Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Memphasys Ltd (MEM)-医療機器分野：企業M&A・提携分析
    Summary Memphasys Ltd (Memphasys), formerly Nusep Holdings Ltd is a bio-separations company that develops and commercializes separation techniques based on its membrane technology. The company develops felix, a non-DNA damaging lab instrument for sperm separation that separates sperm from semen samp …
  • Sterling Bank Plc：企業の戦略・SWOT・財務情報
    Sterling Bank Plc - Strategy, SWOT and Corporate Finance Report Summary Sterling Bank Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Akebia Therapeutics Inc (AKBA)：企業の財務・戦略的SWOT分析
    Summary Akebia Therapeutics Inc (Akebia Therapeutics) is a biopharmaceutical company focused on the development and commercialization of novel therapeutics based on hypoxia inducible factor for patients with kidney disease and other metabolic disorders. Its lead product candidate vadadustat is a HIF …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆